RxDoctor Payments Data

Shonverea Robinson, APRN

Family · Williston, FLNPI 1396280103

Payments from drug & device makers

$1,027in general payments, 2019–2025

Across 41 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$230
  • AbbVie$209
  • Exact Sciences$203
  • Lilly USA, LLC$96
  • GSK$92
  • Pfizer$67
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$1,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$1,727
Medicare patients
55
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$51,386
TrulicityDulaglutide21$43,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$35,975
FarxigaDapagliflozin Propanediol32$34,116
EliquisApixaban41$33,915
XareltoRivaroxaban20$20,188
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,204
SymbicortBudesonide/Formoterol Fumarate29$7,334
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,057
JanumetSitagliptin Phos/Metformin Hcl11$5,916
Advair HfaFluticasone Propion/Salmeterol13$4,004
Albuterol Sulfate HfaAlbuterol Sulfate148$3,982
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,584
Humalog Kwikpen U-100Insulin Lispro11$2,972
Omeprazole98$1,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$230$51,65477 claims
Boehringer IngelheimJardiance$63$51,38646 claims
Lilly USA, LLCTrulicity$96$43,76221 claims
GSKTrelegy Ellipta, Anoro Ellipta$92$43,03264 claims
PfizerEliquis$67$33,91541 claims
MerckJanumet$11$5,91611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Williston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →